2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Effectiveness and safety of a herbal medication, HH368, for clinical symptoms of idiopathic Parkinson’s disease: a randomized controlled, pilot trial protocol

KH. Cho, SW. Kwon, C. Jin, WS. Jung, SK. Moon, SH. Lee (Seoul, Republic of Korea)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Effectiveness on the balance and the walking of a program of home-rehabilitation by digital support versus paper book on Parkinson’s patients: a randomized controlled trial.

M. Moreau, B. Fraudet, P. Gallien, B. Nicolas, E. Leblong (Rennes, France)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Effects of Cognitively Challenging Agility Exercise Program on Clinical and Objective Measures in People with Parkinson’s Disease

P. Carlson-Kuhta, N. Hasegawa, SH. Jung, V. Shah, A. Ragothaman, D. Peterson, K. Smulders, L. King, M. Mancini, J. Lapidus, J. Nutt, F. Horak (Portland, OR, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Effects of gender on caregiving in Parkinson’s disease

S. Horn, S. Wu, Y. Dai, F. Cubillos, N. Dahodwala (Miami, FL, USA)

Caregiver Burden  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats

CA. Pisanò, A. Brugnoli, S. Novello, C. Caccia, C. Keywood, E. Melloni, G. Padoani, S. Vailati, M. Morari (Ferrara, Italy)

Neuropharmacology  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Effects of Virtual Reality Exercise Program using the Sony PlayStation 2 gaming platform on Balance, Emotion and Quality of Life in Patients with Parkinson’s Disease

G-H. Lee (Cheonan, Republic of Korea)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Effects of zonisamide on parkinsonism in patients with dementia with Lewy bodies by severity of cognitive dysfunction and BPSD: subgroup analysis of pooled data from two trials

K. Hasegawa, J. Goldman, T. Odawara, K. Kochi, O. Konishi, H. Maruyama, S. Toya, K. Kosaka, M. Murata, I. Mckeith (Kanagawa, Japan)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson’s disease.

M. Meloni, M. Puligheddu, M. Carta, M. Figorilli, G. Defazio (Cagliari, Italy)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson’s disease.

M. Meloni, M. Puligheddu, A. Cannas, M. Figorilli, G. Defazio, M. Carta (Cagliari, Italy)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson’s Disease.

M. Meloni, M. Figorilli, M. Carta, L. Tamburrino, A. Cannas, M. Fantini, G. Defazio, M. Puligheddu (Cagliari, Italy)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3